Project Grant R01CA304704
Award Date 8/11/25
Completion Date 7/31/29
Dollars Obligated $3M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The University of Southern California received a $650,450 Project Grant from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to develop a novel lung cancer immunotherapy product. The grant will fund the translational development of a tumor-specific T cell receptor-engineered CD4+ T cell product targeting the CT83 cancer-testis antigen, which is expressed in 40-60% of non-small cell lung cancers. The project aims to improve the therapeutic potential of this...
- The U.S. National Cancer Institute (NCI) has awarded a $398,997 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395) to Immunogenik, Inc. to enhance cancer therapeutics with a novel 3-in-1 chimeric antigen receptor (CAR) T cell approach. The research aims to target tumor-associated myeloid cells, which can suppress anti-tumor immune responses, by inhibiting the immunosuppressive LAIR1 signaling pathway. Key deliverables include demonstrating the efficacy of LAIR1...
- The National Cancer Institute awarded a $162,486 Project Grant to Northwestern University to develop "tunable microenvironment-responsive CAR T cells using synthetic gene circuits to enhance potency and safety" for the treatment of ovarian cancer. This grant, funded through the Cancer Research Manpower (CFDA 93.398) program, aims to engineer CAR T cells that can specifically target and treat solid tumors, which have posed challenges for current CAR T cell therapies. The project...
- The National Cancer Institute (NCI), through the Cancer Detection and Diagnosis Research federal grant program (CFDA 93.394), awarded a $244,839 project grant to the University of Virginia. The grant aims to investigate the potential of using magnetic resonance imaging-guided focused ultrasound (MRGFUS) to enhance the delivery and persistence of chimeric antigen receptor (CAR) T cell therapy for pediatric medulloblastoma, a common and challenging brain cancer in children. Under a sub-award,...
- This $195,766 federal Project Grant, awarded on December 19, 2024 by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research at Yale University to develop a mechano-transduction platform for enhancing chimeric antigen receptor (CAR) T-cell therapies for cancer immunotherapy. The key goals are to: 1) measure forces along immune receptors like the T-cell receptor and CAR using force sensors, and 2) engineer force transduction modules that can induce expression of...
- This $438,900 Project Grant was awarded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The grant funds research to develop a "three-cell (T-NK-macrophage) immunotherapy system" using chimeric antigen receptor (CAR) and synthetic cytokine receptor (SCR) technologies. The primary goal is to engineer the three immune cell types to function...
- The University of California, Los Angeles (UCLA) was awarded a $647,632 Project Grant by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) on March 11, 2025. The grant supports research to develop novel "TNF-ALPHA-ARMED" T-cell receptor (TCR) vectors to enhance the efficacy of adoptive cell therapy for solid tumors. Specifically, the research aims to evaluate the impact of transgenic TNF-alpha co-delivery with tumor antigen-specific TCRs or chimeric antigen...
- The National Cancer Institute (NCI), under the federal Cancer Biology Research grant program (CFDA 93.396), awarded a $218,089 Project Grant to the University of California, Santa Barbara (UCSB) to develop and evaluate a novel chimeric antigen receptor macrophage (CAR-M) immunotherapy for the treatment of triple-negative breast cancer (TNBC). The project, titled "RAC-Enhanced Chimeric Antigen Receptor-Macrophage (RACE-CAR-M) Immunotherapy for Triple Negative Breast Cancer," aims to...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $399,958 to Mabswitch Inc., a minority-owned small business, to assess the feasibility of regulating the activation, effector functions, and cytokine release of chimeric antigen receptor (CAR) T-cell therapies. The project aims to develop a "switchable affinity CAR" (SAEFCAR) that can be controlled by an exogenously administered ligand, potentially mitigating the toxicity...
- This $314,685 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of Persistence Therapeutics, Inc.'s novel "SynthNode" approach for CAR T cell therapy. The SynthNode is an implantable device the size of a dime that mimics the function of a lymph node, producing potent, antigen-specific CAR T cells that persist long-term for improved patient outcomes. This fast-track Phase I/II project will complete prototyping,...